Evaluation of protective immune responses induced by DNA vaccines encoding Toxoplasma gondii surface antigen 1 (SAG1) and 14-3-3 protein in BALB/c mice

Meng, Min; He, Shenyi; Zhao, Guanghui; Bai, Yang; Zhou, Huaiyu; Cong, Hua; Lü, Gang; Zhao, Qunli; Zhu, Xing‐Quan

doi:10.1186/1756-3305-5-273

Cited by 69 publications

(59 citation statements)

References 47 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is in agreement with Zaharoff et al (2007) who used b-galactosidase vaccine in either chitosan solution or FIA and reported no significant difference between them. A significant increase in IFN c level was also obtained by Meng et al (2012), Chuang et al (2013), Zhao et al (2013a) and Cong et al (2013).…”

Section: Discussionmentioning

confidence: 76%

The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice

et al. 2014

View full text Add to dashboard Cite

Toxoplasmosis, a zoonotic parasitic disease, is a huge challenge for which there is no effective vaccine up till now. In this study, chitosan nanospheres encapsulated with Toxoplasma lysate vaccine was evaluated for its ability to protect mice against both acute and chronic toxoplasmosis models of infection. Results showed that chitosan nanospheres were equally effective to Freund's incomplete adjuvant (FIA) in enhancing the efficacy of Toxoplasma lysate vaccine. The effectiveness was demonstrated by the delayed death of vaccinated mice following challenge either with virulent RH or avirulent Me49 strains, the significant decrease in parasite density in different organs, significant increase in the humoral and cellular immune response (IgG and IFN c) with a marked reduction of pathological changes in the different organs. However chitosan nanospheres were superior to FIA due to their cost effective preparation and much less necrotic changes induced in the studied organs. The success of chitosan polymer as an alternative to commonly used adjuvants paves the way for the use of other newly developed polymers to be used in the field of vaccine development.

show abstract

Section: Discussionmentioning

confidence: 76%

The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In recent years, DNA vaccination has been demonstrated to elicit a predominantly Th1 immune response: inducing CD4 ϩ T-lymphocyte and CD8 ϩ cytotoxic T-lymphocyte (CTL) responses against the administered antigen (14, 16) and several T. gondii DNA vaccine candidates evaluated using this administration route (17,18,19,20,21,22) have shown effective protection against T. gondii infection. Also, DNA vaccines are promising tools in the development of safe and effective vaccines against T. gondii infection in both humans and animals (14), and thus it would be valuable to identify novel T. gondii antigens for use in DNA vaccination.…”

mentioning

confidence: 99%

Evaluation of Immune Responses in Mice after DNA Immunization with Putative Toxoplasma gondii Calcium-Dependent Protein Kinase 5

Zhang

Huang

et al. 2014

Clin. Vaccine Immunol.

Self Cite

View full text Add to dashboard Cite

dToxoplasma gondii can cause serious public health problems and economic losses worldwide. Calcium-dependent protein kinases (CDPKs) are key mediators of T. gondii signaling pathways and are implicated as important virulence factors. In the present study, we cloned a novel T. gondii CDPK gene, named TgCDPK5, and constructed the eukaryotic expression vector pVAX-CDPK5. Then, we evaluated the immune protection induced by pVAX-CDPK5 in Kunming mice. After injection of pVAX-CDPK5 intramuscularly, immune responses, determined with lymphoproliferative assays and cytokine and antibody measurements, were monitored, and mouse survival times and brain cyst formation were evaluated following challenges with the T. gondii RH strain (genotype I) and the PRU strain (genotype II). pVAX-CDPK5 effectively induced immune responses with increased specific antibodies, a predominance of IgG2a production, and a strong lymphocyte proliferative response. The levels of gamma interferon (IFN-␥), interleukin 2 (IL-2), and IL-12(p70) and the percentages of CD3 ؉ CD4 ؉ and CD3 ؉ CD8 ؉ cells in mice vaccinated with pVAX-CDPK5 were significantly increased. However, IL-4 and IL-10 were not produced in the vaccinated mice. These results demonstrate that pVAX-CDPK5 can elicit strong humoral and cellular Th1 immune responses. The survival time of immunized mice challenged with the T. gondii RH strain (8.67 ؎ 4.34 days) was slightly, but not significantly, longer than that in the control groups within 7 days (P > 0.05). The numbers of brain cysts in the mice in the pVAX-CDPK5 group were reduced by ϳ40% compared with those in the control groups (P < 0.05), which provides a foundation for the further development of effective subunit vaccines against T. gondii.

show abstract

“…DNA vaccines are capable of stimulating the synthesis of antigens in the host cells, in a manner similar to the formation of antigens following a pathogenic microorganism infection. The naturally formed antigen is then processed and modified in a normal manner prior to presentation to the immune system, which subsequently stimulates an immune response (24,25). Therefore, DNA vaccines possess the safety of recombinant subunit vaccines and the high efficiency of live attenuated vaccines in inducing a comprehensive immune response (26), and these immunogenic and protective effects have been demonstrated in numerous animal models and preliminary human clinical trials (27,28).…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine

Wei

Gan

Ren

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. In the present study a eukaryotic expression vector of varicella zoster virus (VZV) glycoprotein E (gE) was constructed and enabled to express in COS7 cells. Furthermore, a specific immune response against the VZV gE eukaryotic expression plasmid was induced in BALB/c mice. The VZV gE gene was amplified using polymerase chain reaction (PCR) and cloned into a eukaryotic expression vector, pcDNA3.1. The recombinant vector was subsequently transfected into COS7 cells using a liposome transfection reagent. The recombinant protein was instantaneously expressed by the transfected cells, as detected by immunohistochemistry, and the recombinant pcDNA-VZV gE plasmid was subsequently used to immunize mice. Tissue expression levels were analyzed by reverse transcription-PCR. In addition, the levels of serum antibodies and spleen lymphocyte proliferation activity were investigated. The amplified target gene included the full-length gE gene (~2.7 kb), and the recombinant expression vector induced gE expression in COS7 cells. In addition, the expression plasmid induced sustained expression in vivo following immunization of mice. Furthermore, the plasmid was capable of inducing specific antibody production and effectively stimulating T cell proliferation. Effective humoral and cellular immunity was triggered in the mice immunized with the VZV gE eukaryotic expression vector. The results of the present study laid the foundation for future research into a VZV DNA vaccine.

show abstract

Evaluation of protective immune responses induced by DNA vaccines encoding Toxoplasma gondii surface antigen 1 (SAG1) and 14-3-3 protein in BALB/c mice

Cited by 69 publications

References 47 publications

The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice

The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice

Evaluation of Immune Responses in Mice after DNA Immunization with Putative Toxoplasma gondii Calcium-Dependent Protein Kinase 5

Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine

Contact Info

Product

Resources

About